Industry Trend Analysis - A Recap On The Pharmaceuticals & Healthcare Outlook For 2017: Western Europe - AUG 2017

BMI View : Drugmakers in Western Europe will need to continue to assess their business strategies, R&D focus and product portfolios. Despite the growing demand for and consumption of high-value medicines in the region, government focus on the cost-effective prescribing of medicines will require companies to seek efficiencies in order to boost revenue streams. It is our view that in addition to employing internal strategies - including the restructuring of business - multinational drugmakers will increasingly participate in discussions regarding drug pricing and sustainable spending.

At the end of 2016, we set out a number of expectations for the coming year in our annual review of the pharmaceuticals and healthcare sector in Western Europe (see 'Pharmaceuticals & Healthcare Outlook For 2017: Western Europe', November 29 2016). We have selected the two key trends and reviewed the progress of each. This article notes our view and details of any developments that support or confirm our outlook. Overall, we expect that these views will continue to play out.

Brexit: Battle Over EMA To Heat Up

This article is part of our Emerging Europe coverage. To access this article subscribe now or sign up for free trial